What is so distinctive about anti-MUSK myasthenia gravis?

Myasthenia gravis (MG) is an iconic neurological disorder. It is classical in its presentation, weakness setting in with exertion and improving with rest. This fatigability is demonstrable in the laboratory when repetitive nerve stimulation (RNS) of the muscles results in a progressively decremental response. Clinically, myasthenia gravis is often a benign disorder which restricts itself to the muscles of the eyes: this ocular MG manifests just with droopy eyelids (ptosis) and double vision (diplopia). At the extreme however is generalised MG, a severe and life-threatening condition that justifies its grave appellation

By Posey & Spiller – Posey & Spiller: Fatigue (Ptosis) in a patient with MG (ed. 1904), Public Domain, Link

Myasthenia gravis depletes the energy reserve of muscles, something which is entirely dependent on acetylcholine (ACh), a chemical released at nerve endings. After release, ACh traverses the neuromuscular junction (NMJ) to attach itself to the acetylcholine receptor (AChR), which is comfortably nestled on the surface of the muscle. This binding of chemical to receptor is a significant event, setting sparks flying, and muscles contracting. In myasthenia gravis, this fundamental process is rudely disrupted by the onslaught of acetylcholine receptor antibodies. These aggressive AChR antibodies, produced by the thymus gland in the chest, vent their rage by competitively binding to the receptor, leaving acetylcholine high and dry. Eventually, the rampaging antibodies destroy the receptor in an act of unjustified savagery.

Drosophilia Neuron. NICHD on Flickr. https://www.flickr.com/photos/nichd/29596368551/

In tackling myasthenia gravis, it is no wonder that neurologists first have to hunt down the ferocious AChR antibodies. They whisk off an aliquot of serum to a specialist laboratory, but waste no time in planning a counteroffensive, confident that the test will return as positive. The strategy is to boost the level of acetylcholine in the NMJ, tilting the balance in favour of ACh against the antibodies. The tactic is to zealously despatch a prescription for a drug that will block acetylcholine esterase inhibitor, the enzyme which breaks down acetylcholine. The neurologist then closely observes the often dramatic response, one of the most gratifying in clinical medicine; one minute as weak as a kitten, the next minute as strong as an ox. MG is therefore one disorder which debunks the wicked jibe that neurologists know so much…but do so little to make their patients better!

Drosophilia Neuromuscular Junction. NICHD on Flickr. https://www.flickr.com/photos/nichd/34754479075

Unfortunately for the neurologist, every now and then, the AChR antibody test result comes back as negative. In the past, the dumbfounded and befuddled, but nevertheless undaunted neurologist, will march on, battling a diagnosis of antibody-negative MG. Nowadays however, this not a comfortable diagnosis to make because AChR antibody is no longer the only game in town. We now know that there are many other antibodies that are jostling for commanding positions in the anti-myasthenia coalition. These include anti LRP4, cotarctin, titin, agrin, netrin 1, VGKC, and ryanodine. However, the clear frontrunner in this melee is anti-MUSK antibody, responsible for 30-50% of MG in which there are no AChR antibodies.

By PyMol, CC0, Link

Anti MUSK syndrome has many distinguishing features that set it apart from the run-of-the-mill myasthenia gravis. Below are five distinctive markers of anti-MUSK syndrome:

  1. Subjects with anti-MUSK syndrome are typically middle-aged women in their 3rd or 4th decades. This is younger than the usual age of people with AChR MG. Indeed neurologists now recognise typical myasthenia as a disease of older people.
  2. People with anti-MUSK syndrome present with acute and prominent involvement of head and neck muscles. This results in marked swallowing and breathing difficulties. They are therefore at a higher risk of myasthenia crisis.
  3. Single fiber electromyogram (sfEMG), a specific and reliable neurophysiological test of MG, is often normal in anti-MUSK syndrome. This is partly because the limb muscles are usually spared in anti MUSK syndrome.
  4. People with anti-MUSK myasthenia often do not benefit from, nor do they tolerate, the  acetylcholinesterase inhibitors which are used to treat MG. Indeed, these drugs may worsen anti-MUSK syndrome.
  5. Thymectomy, removal of the thymus gland, is not beneficial in people with anti-MUSK syndrome, unlike its usefulness in AChR MG.
Thymus gland 2. RachelHermosillo on Flickr. https://www.flickr.com/photos/rachelhermosillo/5388860587

All this is just the tip of the evolving myasthenia gravis iceberg. You may explore more of myasthenia in our previous blog posts:

How is innovative neurology research energising myasthenia?

What is the startling research unsettling the treatment of myasthenia gravis?

What is the relationship of pregnancy to myasthenia gravis?

Is Zika virus infection a risk factor for myasthenia gravis?

What does the EMG show in LRP4 myasthenia gravis?

What’s evolving at the cutting-edge of autoimmune neurology?

What are the most iconic neurological disorders?


You may also explore anti-MUSK, and all the other myasthenia gravis subtypes, in neurochecklists. Go on…you know you want to know more!

Antibody lights. Isabelle on Flickr. https://www.flickr.com/photos/diamondgeyser/456900567/


How is innovative neurology research energising myasthenia?

Myasthenia gravis (MG) is one of the best characterised neurological disorders. The hallmark of MG is fatigable weakness. This manifests as intermittent ptosis (droopy eyelids), diplopia (double vision), and limb weakness. There are two main types-ocular MG affects just the eyes and eyelids, and generalised MG affects the body, including the bulbar functions of  breathing and swallowing.

By Doctor Jana - http://docjana.com/#/nmj, CC BY 4.0, https://commons.wikimedia.org/w/index.php?curid=46835961
By Doctor Jana – http://docjana.com/#/nmj, CC BY 4.0, https://commons.wikimedia.org/w/index.php?curid=46835961


The problem in MG is straightforward lack of communication; the nerves and muscles aren’t talking to each other. The two meet up at the neuromuscular junction (NMJ) where the nerves send packages of acetylcholine to bind with acetylcholine receptors (AChR) on the surface of the muscles. The muscles usually acknowledge this by contracting and producing action, but in MG this response is blocked by antibodies to the acetylcholine receptor (AChR antibodies). Like all culprits, it has wily accomplices such as anti-muscle specific kinase (anti-MUSK) antibody.

By No machine-readable author provided. S. Jähnichen assumed (based on copyright claims). - No machine-readable source provided. Own work assumed (based on copyright claims)., Public Domain, https://commons.wikimedia.org/w/index.php?curid=423915
By No machine-readable author provided. S. Jähnichen assumed (based on copyright claims). – No machine-readable source provided. Own work assumed (based on copyright claims)., Public Domain, https://commons.wikimedia.org/w/index.php?curid=423915


AChR antibodies are produced by a gland in the chest called the thymus. Disturbingly, this rather shabby-looking tissue may become enlarged (thymic hyperplasia), or cancerous (thymoma). The neurologist is therefore quick to request a CT chest scan as soon as MG is confirmed. Alas, the thymus is often normal or even shrivelled, to the delight of the patient who escapes the cardiothoracic surgeon. The neurologist is however ambivalent because surgery often gives a one-off cure, and saves the neurologist from a life-long commitment to monitor toxic treatments. The life of a Neurologist!

With so much known about MG, one would think there is very little on the horizon to put a smile on the faces of people with MG. But this old dog still has a few new tricks, and here are 4 energising reports I came across.

1. Predicting generalisation of ocular MG

By BruceBlaus. When using this image in external sources it can be cited as:Blausen.com staff. "Blausen gallery 2014". Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762. - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=29452230
By BruceBlaus. When using this image in external sources it can be cited as:Blausen.com staff. “Blausen gallery 2014“. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762. – Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=29452230


Neurologists are aware that ocular MG could transform to generalised MG, they just don’t know who is at risk. Generalised MG is obviously a worse condition and requires more heavy-duty treatments. After much speculation, a report in JAMA Neurology has found the predictor of MG generalisation. Titled Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis, the authors confirmed, for the first time ever, that the risk of generalisation is linked to higher AChR antibody levels. I know, you were expecting some new, cutting-edge test or technology: sorry for the dampener, but sometimes it’s the little things that count. 

2. Linking MG to muscular dystrophy

By Cbenner12 - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=19555962
By Cbenner12Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=19555962


Congenital myasthenia is a slightly different kettle of fish from conventional MG. For one, the diversity of genetic mutations that cause congenital myasthenia is mind-boggling; there are >20 genetic forms of MG such as DOK 7, RAPSYN, LAMB 2, and AGRIN. And these all differ in their presentation and response to treatment. An addition to this long list of congenital myasthenic syndromes should therefore normally not be exciting news. But there is something different in the recent report in the journal Brain about GMPPB (you really don’t want to know what this stands for). The paper, titled Mutations in GMPPB cause congenital myasthenic syndrome, opens up a can of worms because GMPPB also plays a role in causing muscular dystrophy. The authors see this as a bridge between myasthenia and muscular dystrophy. All rather complicated stuff, not quite sure what the implications are, but that’s the reason neurologists exist!

3. Leflunomide for drug-resistant MG

By MarinaVladivostok - Own work, CC0, https://commons.wikimedia.org/w/index.php?curid=27488894
By MarinaVladivostokOwn work, CC0, https://commons.wikimedia.org/w/index.php?curid=27488894


Immunosuppression is the ultimate treatment for MG because it reduces the production of the MG-causing antibodies. And the neurologist has a list, an arm length, of immunosuppressive agents to try. This variety of options is helpful because earlier choices may be ineffective, intolerable, or impractical. Azathioprine, methotrexate, mycophenolate …these roll out easily from the neurologist’s pen. Leflunomide would however sound very strange in neurological circles; it is more familiar to rheumatologists who use it to treat rheumatoid arthritis. Neurologists, ever peeping into the rheumatology recipe book, thought why not try Leflunomide in MG. They reported their findings in Journal of Neurology as Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. And the recipe worked; 9 of 15 people with severe, steroid-dependent, MG improved on Leflunomide. Great news for when the going gets tough.

3, 4 Diaminopyridine for anti-MUSK MG

Thankfully not all MG treatment involves immunosuppression. One approach is to prevent the break down of the enzyme (esterase) that breaks down acetylcholine-got it? In this way there will be more acetylcholine available to counter the effect of AChR antibodies. Medications that work in this way are called acetylcoline esterase inhibitors (ACEI). It’s OK to  re-read all this before proceeding!

Pyridostigmine is the quintessential ACEI. But this is not effective in the more severe anti-MUSK MG where typical MG treatments don’t work so well. Neurologists have tried all sorts, including Rituximab, to varying success. What to do when all fails? A paper in the journal Neurology offers some hope that anti-MUSK MG may respond to 3,4 Diaminopyridine. This will be heart-warming news to all neurologists, if they ignore the fact that it is a single case report! But hey, from little acorns grow giant oak trees.

Want to dig deeper into MG? Try this update on myasthenia gravis.